<DOC>
	<DOCNO>NCT01502527</DOCNO>
	<brief_summary>Based previous data publish SERM property Femarelle , investigator hypothesize Femarelle could potential treatment Vulvo-vaginal atrophy ( VVA ) symptom . The current study pilot study examine effect Femarelle® VVA symptom symptomatic post-menopausal woman .</brief_summary>
	<brief_title>A Twelve Week Study Investigate Efficacy Femarelle® , Treatment Post Menopausal Vaginal Atrophy</brief_title>
	<detailed_description>Post-menopausal woman age 54-77 , vaginal atrophy ( &lt; 5 % superficial cell cervical cytology ) least one moderate-to-severe VVA symptom ( dryness , irritation , soreness , dysuria , dyspareunia , bleed coitus ) , recruit 12-week open-label pilot study . The study protocol approve Schulman Associates IRB.Femarelle give twice daily subjective symptom well objective measure like inspection vaginal pH measure .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<criteria>Healthy post menopausal woman age 4085+yrs complain vaginal dryness least three urogenital symptom follow : vaginal dryness , vaginal irritation , vaginal soreness , dysuria , dyspareunia , bleed coitus &amp; one symptom must moderate severe determine patient , Moderate : discomforting aware activity . Severe : discomforting enough interfere activity Activities include sit , walk , run , urinating , well sexual activity BMI 1834 ( inclusive ) . Patients LMP least one year ago , either natural surgical . Patients normal mammogram within 9 month prior enrollment . Patients able adhere visit schedule protocol requirement available complete study . Patients provide write informed consent participate study . FSH &gt; 40 mIU/m . Estradiol &lt; 20 pg/ml . Vaginal PH &gt; 5 . &lt; 5 % superficial cell assess vaginal cytology . Normal pelvic breast exam investigator . Patients use HRT ( use past 3 month ) . Patients consume last three month high soy diet food compound sell remedy post menopausal symptom . Any history significant cancer precancer , neurological , renal , cardiovascular , respiratory ( e.g . asthma , COPD ) , hypercoagulability , hematopoietic disease , immune deficiency clinically significant medical disorder , investigator 's judgment contraindicate administration study medication . Patients clinically significant abnormality upon examination screen visit . Patients known history drug alcohol abuse . Known hypersensitivity and/or allergy soy flax . Participation another clinical trial within past 30 day .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Vulvo vaginal atrophy</keyword>
	<keyword>Femarelle</keyword>
</DOC>